Timothy Springer, PhD, Founder, Morphic Therapeutic is Latham Family Professor at Harvard Medical School and Professor of Medicine at Children’s Hospital Boston.

Tim Springer, Ph.D. – an immunologist and biophysicist serving as Latham Family Professor at Harvard Medical School and Boston Children’s Hospital – discovered integrins and their ligands in the 1980s and since then, has worked on elucidating regulation of their biological function. His pioneering work resulted in the detailed characterization of integrin structure and robust understanding of biophysical phenomena underlying their activation. This has led to the founding of multiple biotechnology companies (LeukoSite , Scholar Rock, Morphic Therapeutic) and approved therapeutics including Amevive®, Raptiva®, Campath®, Velcade®, and Entyvio®). Morphic Therapeutic Inc., capitalizes on his 15 years of study of the molecular mode of action underlying unproductive interactions between small-molecule drugs and their integrin targets in the disease tissue. These findings make possible small molecule antagonists which reverse their activation by preventing them from occupying disease-specific signaling and conformational states. Tim is a member of Morphic Board of Directors and Scientific Advisory Board and provides strategic guidance to all research and development activities of Morphic Therapeutic.